Zenas BioPharma

Edit info

Founded:

Location: Shanghai , China

Employee range: 0 - 0

Clinical stage: Clin3

Therapy area: IgG4-realted disease

Drug types: IMM, HEM, OPH

Lead product: Obexelimab

Funding: $118M B Nov 2022

Investors: Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners, Superstring Capital, Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, Xencor

zenasbio.com

linkedin.com

job board

Business:

Immune-Based Therapies

Drug notes:

Also Clin2 warm autoimmune hemolytic anemia, Clin2 undisclosed; ZB001/011 Clin2 thyroid eye disease; ZB002 Clin1 autoimmune condition; ZB005 Clin1 autoimmune condition; ZB004 Clin0 autoimmune condition

About:

Zenas BioPharma is a biopharmaceutical company dedicated to advancing therapies for autoimmune disorders and rare diseases, serving patients and physicians globally. Their antibody-based therapeutics are produced for those with high unmet medical needs. Their immunology-focused programs modulate B cells and other immune system components for the treatment of various diseases such as Multiple Sclerosis, Systemic Lupus, and Anemia that have no cures and limited treatment options. Through the depletion of malfunctioning B cells, these therapeutics could produce more potent, long-lasting effects compared to the current traditional medicines. The overall mission of Zenas is to develop and deliver innovative therapies for inflammatory and immune-mediated diseases worldwide.